Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talks to Proactive following the release of full year results for calendar year 2022 - a year he says was "quite challenging at times." Marsden discusses the UK-based respiratory company's clinical development plan to take the SNG001 drug through Phase 3 trials and registration.

The drug is being developed to help patients with respiratory viruses such as influenza virus, RSV, and SARS- CoV-2. The plan was formulated after a year of data collection and consultation with experts. He also highlights the company's relatively strong cash position, which he says will "allow [Synairgen] to get on with" its planned work schedule.

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com